Skip to main content
Clinical Trials/EUCTR2015-003250-41-GB
EUCTR2015-003250-41-GB
Active, not recruiting
Phase 1

Protection induced by Live Attenuated Influenza Vaccine (LAIV or Fluenz Tetra) - applied epidemiological study - LAIV PROTECT

Public Health England0 sites2,500 target enrollmentFebruary 8, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Public Health England
Enrollment
2500
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 8, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Healthy children aged 10 to 16 (born between 1/9/2005 and 1/9/1999\) or staff at the participating school sites of any age
  • \- Children must be enrolled and attending one of the two schools study sites in the 2015/16 school year.
  • \- Staff must be working at one of the 2 school study sites in the 2015/16 school year.
  • \- Relevant consent, parental/guardian consent and participant assent or participant consent (age dependant)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 0
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range 0

Exclusion Criteria

  • \- Any current or previous condition/circumstance that, in the opinion of the investigator, may put the individual at risk if participating in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials